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Abstract
The down-regulation of microRNA-196b (miR-196b) has been reported, but its contribution to cervical cancer progression
remains to be investigated. In this study, we first demonstrated that miR-196b down-regulation was significantly associated
with worse disease-free survival (DFS) for cervical cancer patients treated with combined chemo-radiation. Secondly, using a
tri-modal approach for target identification, we determined that homeobox-B7 (HOXB7) was a bona fide target for miR-
196b, and in turn, vascular endothelial growth factor (VEGF) was a downstream transcript regulated by HOXB7.
Reconstitution of miR-196b expression by transient transfection resulted in reduced cell growth, clonogenicity, migration
and invasion in vitro, as well as reduced tumor angiogenesis and tumor cell proliferation in vivo. Concordantly, siRNA
knockdown of HOXB7 or VEGF phenocopied the biological effects of miR-196b over-expression. Our findings have
demonstrated that the miR-196b/HOXB7/VEGF pathway plays an important role in cervical cancer progression; hence
targeting this pathway could be a promising therapeutic strategy for the future management of this disease.
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Introduction
Worldwide, cervical cancer is the third most frequently
diagnosed malignancy and the fourth leading cause of cancer
mortality in women, with an estimated 530,000 new cases and
275,000 deaths each year [1]. Although cervical cancer incidence
and mortality rates have declined over the past thirty years in the
United States [2], the 5-year survival rate has remained below
40% for patients diagnosed with Stage III or IV disease [3]. Novel
insights are required to better understand the mechanisms that
contribute to disease progression, in order to design improved
therapies for patients with locally advanced cervical cancer.
Micro-RNAs (miRNAs) are short, non-coding RNAs that
regulate gene expression post-transcriptionally [4,5], and aberrant
miRNA expression has been shown to be important in many
human malignancies [6]. Gene targets that contribute to tumor
progression have been described for several miRNAs [7,8,9];
however, the biological function of the majority of miRNAs still
remains unknown. One of the major challenges to miRNA target
identification is the ability of miRNAs to bind mRNA targets with
imperfect complementarity; hence a single miRNA can potentially
regulate several hundreds or thousands of genes [10]. Unfortu-
nately, the currently available in silico miRNA target prediction
algorithms have high false-discovery and false-negative rates
[11,12]; thereby mandating experimental validation of miRNA
targets.
Down-regulation of miR-196b in cervical cancer has been
previously reported [13], but its role in tumor progression in this
disease has not been previously investigated. Herein, we report
down-regulation of miR-196b in primary human cervical cancer
tissues and cell lines. Furthermore, we identified the HOXB7
transcription factor as a novel, direct and specific target of miR-
196b, which in turn, regulates VEGF in cervical cancer. Most
importantly, miR-196b down-regulation was associated with worse
DFS in patients treated with chemo-radiation, highlighting the
biological importance of miR-196b in cervical cancer progression.
Materials and Methods
Ethics Statement
Written informed consent was obtained from patients, accord-
ing to a protocol approved for this study by the University Health
Network Research Ethics Board. Experiments with animals were
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carried out in strict accordance with the protocol approved by the
Animal Care Committee (ACC) of the Ontario Cancer Institute,
University Health Network (Animal Use Protocol: 342.18).
Cell Lines and Transfections
Human cervical cancer cell lines (ME-180, SiHa, and HT-3)
were obtained from American Type Culture Collection (ATTC),
and grown in a-MEM supplemented with 10% FBS at 37uC, 5%
CO2. All cells were authenticated every six months at the Centre
for Applied Genomics (Hospital for Sick Children, Toronto,
Canada) using the AmpF/STR Identifier PCR Amplification Kit
(Applied Biosystems), and determined to be free from Mycoplasma
contamination using the MycoAlert Mycoplasma Detection Kit
(Lonza). ME-180 and SiHa cells were transfected using the
LipofectAMINE 2000 (Invitrogen) forward transfection protocol,
according to the manufacturer’s instructions. Pre-miR Negative
Control #1 (NC), Pre-miR-196b (Ambion), All Stars Negative
Control (siNEG), siHOXB7 and siVEGF (Qiagen) were all
transfected at a final concentration of 30 nmol/L.
miRNA Expression Profiling of Cell Lines
Total RNA was isolated from SiHa, ME-180 and HT3 cervical
cancer cell lines using the mirVana miRNA Isolation Kit (Ambion)
according to the manufacturer’s instructions. FirstChoiceH Total
RNA: Human Normal Cervix Tissue (Ambion) from 3 different
tissue donors was utilized as normal comparators. Expression
levels of 377 miRNAs and 3 snoRNAs (controls) were assayed in
the cervical cancer cell lines and normal cervix tissues using the
TaqManH Low Density Array (TLDA) Human MicroRNA Panel
(Applied Biosystems), with the Applied Biosystems 7900HT Real-
Time PCR System, as we have previously described [14].
miRNA Expression Profiling of Patient Tissues
Flash-frozen punch biopsies were obtained from patients with
locally advanced cervical cancer who were planned to receive
primary treatment with standard chemo-radiation, consisting of
external-beam radiotherapy to the primary cervical tumor and
pelvic lymph nodes (45 to 50 Gy total, in 1.8-to-2-Gy daily
fractions with 18-to-25-MV photons), combined with weekly doses
of cisplatin (40 mg/m2 total, 5 doses). FIGO (International
Federation of Gynecologists and Obstetricians) staging was
determined using a combination of: pretreatment evaluation
under anesthesia, computed tomography (CT) scans of the
abdomen and pelvis, chest x-ray, and magnetic resonance imaging
(MRI) of the pelvis. MRI was also used to determine lymph node
status; pelvic and para-aortic lymph nodes were classified as
Table 1. Clinical parameters of 79 cervical cancer patients.
Category Subcategory N=79 Percent
Age, years Median 48
Range 26–84
Tumour size #5 cm 48 61%
.5 cm 31 39%
FIGO stage IB 24 30%
IIA 2 3%
IIB 35 44%
IIIA 0 0%
IIIB 18 23%
Histology Squamous 74 94%
Adenocarcinoma 4 5%
Adenosquamous 1 1%
Pelvic node involvement Positive 25 32%
Equivocal 15 19%
Negative 39 49%
doi:10.1371/journal.pone.0067846.t001
Figure 1. miR-196b down-regulation in cervical cancer. A) miR-
196b expression levels were measured using qRT-PCR in 79 primary
cervical cancer samples, compared to 11 normal cervix epithelial tissue
controls. B) Kaplan-Meier analysis of DFS in patients with cervical
cancer. Red, patients with higher than median miR-196b expression
level (n = 39); blue, patients with lower than median miR-196b
expression (n = 39); one patient was removed from survival analysis
due to missing survival information. C) Basal levels of miR-196b in three
cervical cancer cell lines (SiHa, ME-180, and HT-3), as compared to
normal cervix epithelial tissues, assayed by qRT-PCR. **P,0.01.
doi:10.1371/journal.pone.0067846.g001
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Figure 2. In vitro effects of miR-196b over-expression. A) Relative viability of ME-180 and SiHa cells were assessed at 48 and 72 hours post-
transfection with pre-miR-196b (30 nmol/L), compared to Negative Control pre-miR (30 nmol/L), using the Trypan Blue assay. B) Clonogenicity of ME-
180 and SiHa cells were assessed by transfection with 30 nmol/L of pre-miR 196b or Negative Control pre-miR. At 48 hours post-transfection, cells
HOXB7 Is a Target of miR-196b in Cervical Cancer
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positive for metastatic disease if the MRI short-axis dimension was
.1 cm and equivocal if it was 8 to 10 mm. After biopsy, the
specimens were placed in optimal cutting temperature (OCT)
storage medium for histopathologic examination, then flash-frozen
in liquid nitrogen. H&E-stained tissue sections were cut from the
OCT-embedded material and evaluated by a gynecologic
pathologist (B Clarke). Total cell content (stroma and tumor cells)
was estimated for all tissue samples using a light microscope, and
only samples containing .70% tumor cells were considered for
further analysis (n = 79). The clinical characteristics of these 79
patients are provided in Table 1. The median follow-up time for
this cohort was 3 years. Flash-frozen normal cervix tissues
obtained from 11 patients who underwent hysterectomy for
benign causes served as normal comparators.
Two sections of 50-micron thickness were cut from the OCT-
embedded flash-frozen tissues and placed in a nuclease-free
microtube. Total RNA was isolated using the Norgen Total
RNA Purification Kit (Norgen Biotek), according to the manu-
facturer’s instructions. Global miRNA expression was measured in
the cervical cancer and normal cervix tissues with the TaqManH
Low Density Array (TLDA) Human MicroRNA A Array v2.0
(Applied Biosystems) using the Applied Biosystems 7900HT Real-
Time PCR System, as already described [14].
Quantitative Real-time PCR Analysis of miRNAs and
mRNAs
Total RNA was isolated from the cell lines using the Total RNA
Purification Kit (Norgen Biotek), according to the manufacturer’s
instructions. The expression of miR-196b was measured by
quantitative real-time polymerase chain reaction (qRT-PCR)
using the standard TaqMan MicroRNA Assay (Applied Biosys-
tems). Briefly, RNA was first reverse transcribed using the
TaqMan MicroRNA Reverse Transcription (RT) Kit and a
stem-loop primer specific for miR-196b (Applied Biosystems) [15].
The 2-DDCt method was used to calculate relative levels of miR-
196b expression, using RNU44 as a reference gene [16].
The RT products were amplified with miR-196b-specific
primers, as we previously described [14]. The expression levels
of previously-described (c-myc, BCL2, HOXA9, MEIS1), and
candidate mRNA targets for miR-196b (ANKHD1, CTDSP2,
FGFR1, HDAC, HOXA7, HOXB7, KRT8, PUM2, SLC9A6,
SMC3, SMG7, SR140), and HOXB7 (VEGF, Ku70, Ku80,
DNA-PK, FGF2, MMP2, WNT5a, PDGFA, THBS2) were also
measured by qRT-PCR. One microgram of total RNA was
reverse-transcribed using SuperScript II Reverse Transcriptase
(Invitrogen) according to the manufacturer’s instructions. Quan-
titative RT-PCR was performed using SYBR Green PCR Master
Mix (Applied Biosystems) and PCR primers (Table S1) designed
using Primer 3 Input. The 2-DDCt method was used to calculate
relative levels of gene expression, with GAPDH as a reference
gene [16].
Cell Viability, Proliferation and Colony-Forming Assays
The viability of transfected cells was assessed by the Trypan
blue exclusion assay. ME-180 and SiHa cells were transfected in
triplicate with 30 nmol/L of pre-miR-196b, NC, siHOXB7,
siVEGF, or siNEG and incubated at 37uC, 5% CO2. At 48 and
72 hours post-transfection, cells were trypsinized, stained with
Trypan blue and counted using a hemocytometer. Cell prolifer-
ation was examined using the CellTiter 96 Non-Radioactive Cell
Proliferation Assay (MTS Assay) (Promega BioSciences), according
to the manufacturer’s instructions. For colony formation assays,
cells were transfected with 30 nmol/L of pre-miR-196b, Pre-miR
Negative Control #1, siHOXB7, siVEGF, or siNEG and
incubated at 37uC, 5% CO2. At 48 hours post-transfection, cells
were re-seeded at low density in 6-well plates in triplicate. Cells
were incubated at 37uC, 5% CO2 for 10–12 days, then fixed and
stained with 0.1% crystal violet in 50% methanol. The number of
colonies containing at least 50 cells was counted, and the surviving
fraction was calculated by comparison with cells transfected with
Negative Control.
Cell Migration and Invasion Assays
BD BioCoat Matrigel Invasion Chambers and Control Inserts
(BD Biosciences) were used to assay migration and invasion of
transfected cells. Chambers contained a polyethylene terephthal-
ate membrane with 8 mm pores. ME-180 and SiHa cells were
transfected with 30 nmol/L of pre-miR-196b, NC, siHOXB7,
siVEGF, or siNEG and incubated at 37uC, 5% CO2. At 24 hours
after transfection, 1.56105 cells were re-seeded inside each
chamber with medium containing low serum (1% FBS). The
chambers were placed in a 24-well plate, with high serum (20%
FBS) medium in each lower chamber to serve as a chemo-
attractant. Cells were incubated at 37uC, 5% CO2 for 48 hours,
then the membranes were washed, stained, and mounted onto
slides. A light microscope was used to count the number of
migrating or invading cells. Relative migration was calculated by
comparison with cells transfected with the negative control.
Percent invasion was calculated as the number of cells that
invaded through the Matrigel insert, divided by the number of
cells that migrated through the control insert.
Cell Cycle Analysis
Cell cycle analysis was performed on ME-180 and SiHa cells
after transfection with 30 nmol/L of pre-miR-196b or NC, to
measure the fraction of cells in the sub-G1 phase of the cell cycle.
Cells were harvested and washed twice in FACS buffer (PBS/0.5%
BSA), re-suspended in 1 mL of FACS buffer, then fixed in 1 mL of
ice-cold 70% ethanol. After 1 h of incubation on ice, cells were
washed again and re-suspended in 500 uL of FACS buffer
containing 40 mg/mL RNase A (Sigma) and 50 mg/mL propidium
iodide, then incubated in the dark at room temperature for 30
minutes. Cells were analyzed in the BD FACScalibur (Becton
Dickinson) using the FL-2A and FL-2W channels. The flow
cytometry data were analyzed using FlowJo 7.5 software (Tree
Star).
were harvested then counted and re-seeded at low density in 6-well plates. After 10 days of incubation, cells were fixed and stained and the number
of colonies (.50 cells) were counted. C) Relative proliferation of ME-180 and SiHa cells were examined at 24, 48, and 72 hours post-transfection with
pre-miR-196b (30 nmol/L), compared to Negative Control pre-miR (30 nmol/L), using the MTS assay. D) Representative images (left) and histograms
(right) depicting migratory ability (top) and invasiveness (bottom) of ME-180 cells that were transfected with 30 nmol/L of pre-miR 196b or Negative
Control pre-miR, harvested at 24 hours post-transfection, then counted and re-seeded in the invasion chambers. Cell migration (top), and invasion
(bottom), assessed at 48 hours after seeding in transwell chambers. All data represent the mean6 SEM from 3 independent experiments. NC, pre-miR
Negative Control; *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0067846.g002
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Figure 3. Identification of HOXB7 as an mRNA target of miR-196b. A) Relative luciferase activity of ME-180 or SiHa cells at 24 hours after co-
transfection with pMIR-REPORT, pMIR-HOXB7 or pMIR-HOXB7-mut vectors and pre-miR-196b or NC (30 nmol/L). B) Relative HOXB7 mRNA expression
levels in ME-180 or SiHa cells after transfection (48, and 72 hrs) with pre-miR-196b or NC (30 nmol/L), as measured by qRT-PCR. Expression levels were
HOXB7 Is a Target of miR-196b in Cervical Cancer
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In vivo Experiments
Six- to 8-week-old severe combined immunodeficient (SCID)
female mice were utilized for xenograft experiments, according to
guidelines of the Animal Care Committee, Ontario Cancer
Institute, University Health Network. Cells were transfected with
pre-miR-196b or NC and incubated at 37uC, 5% CO2. At 48
hours post-transfection, cells were harvested and 56105 viable cells
were diluted in 100 mL of growth medium. Cells were injected
intramuscularly into the left gastrocnemius muscle of female SCID
mice. Tumor plus leg diameter was measured twice a week and
mice were euthanized when 15 mm was attained. Tumors were
removed at 25 days after implantation and immediately fixed in
10% buffered formalin for 24 h, placed in 70% ethanol for 24 h,
embedded in paraffin, and sectioned (5 mM) for immunostaining.
In addition to hematoxylin and eosin (H&E) staining, cluster of
differentiation 31 (CD31) was used for assessing tumor angiogen-
esis, Ki-67 for tumor cell proliferation, and terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end labeling (TUNEL)
for apoptosis.
Tri-modal Approach for miRNA Target Identification
Candidate mRNA targets of miR-196b were determined using a
previously-described tri-modal approach [8] combining: i) all
predicted targets of miR-196b from five in silico miRNA target
prediction databases (TargetScan, PicTar, GenMir++, miRBase,
miRDB); ii) mRNAs up-regulated at least 2-fold in cervical cancer
tissues compared to normal cervix tissues, using two independent
publicly-available microarray datasets [17,18]; and iii) mRNAs
normalized to GAPDH expression. C) Representative Western blot image (top), and relative quantification of HOXB7 protein levels (bottom) after
transfection (48, and 72 hrs) with pre-miR-196b or NC (30 nmol/L). All data represented the mean 6 SEM from 3 independent experiments. OD,
optical density; NC, pre-miR Negative Control; *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0067846.g003
Figure 4. Identification of VEGF as a target of the HOXB7 transcription factor. A) Relative VEGF expression at the mRNA level after
transfection of ME-180 or SiHa cells with siHOXB7 or siNEG (30 nmol/L), as determined by qRT-PCR. Expression levels were normalized to GAPDH
expression. B) Relative levels of secreted VEGF protein after transfection of ME-180 or SiHa cells with siHOXB7 or siNEG (30 nmol/L), as determined by
ELISA. All data represented the mean 6 SEM from 3 independent experiments. siNEG, All Stars Negative Control; *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0067846.g004
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Figure 5. Downstream effects of siHOXB7 and siVEGF. ME-180 and SiHa cells were transfected with siHOXB7, siVEGF or siNEG (30 nmol/L): A)
Relative cell viability assessed using the Trypan blue assay at 48 and 72 hours post-transfection with siHOXB7 (left) or siVEGF (right); B) Cells were
harvested at 48 hours post-transfection, then counted and re-seeded at low density in 6-well plates; after 10 days of incubation, cells were fixed and
stained and colonies (.50 cells) were counted. Histograms depict the relative number of surviving colonies post-transfection with siHOXB7 (left), and
siVEGF (right). C) Representative images (left) and histograms (right) depict migratory ability (top), and invasiveness (bottom) after transfection. All
data represented the mean 6 SEM from 3 independent experiments. siNEG, All Stars Negative Control; *P,0.05.
doi:10.1371/journal.pone.0067846.g005
HOXB7 Is a Target of miR-196b in Cervical Cancer
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down-regulated at least 0.5-fold at both 24 and 72 hours after
transfection with 30 nmol/L of pre-miR-196b, where transcript
levels were measured using the Whole Human Genome 4644 K
One-Color Array (Agilent).
Luciferase Reporter Assay
Wildtype or mutant fragments of the 39-untranslated region
(UTR) of HOXB7 containing the predicted binding site (position
220–226) for miR-196b were individually amplified by AmpliTaq
Gold DNA Polymerase (Applied Biosystems) using the primers
listed in Table S1. The PCR products were purified, then cloned
downstream of the firefly luciferase gene in the pMIR-REPORT
vector (Ambion) at the SpeI and HindIII restriction sites, to produce
the pMIR-HOXB7 or pMIR-HOXB7-mut vector. ME-180 and
SiHa cells were co-transfected with 100 nmol/L of pre-miR-196b
or NC, and 100 ng of the reporter vector of interest. As a
reference control, 50 ng of pRL-SV vector (Promega) containing
the Renilla luciferase gene was also transfected with each condition.
Firefly and renilla luciferase activities were measured at 24 hours
post-transfection using the Dual-Glo Luciferase Assay System
(Promega) according to the manufacturer’s instructions.
Immunoblotting
Cells were transfected with either 100 nmol/L of pre-miR-196b
or NC, and total protein extracts were harvested on ice after 48
and 72 hours. Proteins of interest were probed with rabbit anti-
HOXB7 (1:500 dilution; Invitrogen) or mouse anti-GAPDH
(1:10,000 dilution; Sigma), and detected with IRDye fluorescent
secondary antibodies (1:20,000 dilution, LI-COR). GAPDH was
used as a loading control. Immunoblots were scanned and
quantified using the Odyssey Infrared Imaging System (LI-COR).
Enzyme-linked Immunosorbent Assay (ELISA)
Cells were transfected with 30 nmol/L of siHOXB7 or siNEG,
and the level of secreted VEGF was measured at 48 and 72 hours
post-transfection, using the Human VEGF DuoSet ELISA (R&D
Systems) according to manufacturer’s instructions.
5-aza-29-deoxycytidine Treatment
ME-180 and SiHa and were seeded in 24-well plates and
incubated overnight at 37uC, 5% CO2. Media containing 2 mM 5-
aza-29-deoxycytidine (5-aza-DCT) (Sigma-Aldrich) was added to
cells, 1 and 3 days after seeding, respectively. Cells were harvested
4 days after seeding and total RNA was isolated for qRT-PCR
analysis of miR-196b expression.
Statistical Analysis
All experiments have been performed at least three independent
times, and the data are presented as the mean 6 standard error of
the mean (SEM). The Student’s t-test function (unpaired, two-
tailed) in Microsoft Excel (Microsoft, Redmond, WA) was used to
compare two treatment groups. Graphs were plotted using
GraphPad Prism software (GraphPad software, San Diego, CA).
The Kaplan-Meier method was used for univariate analysis, and
the log-rank test was used to examine associations between miR-
19b expression and DFS, where the expression was dichotomized
at the median value. The relationship between tumor size and
miR-196b expression was investigated using Pearson’s correlation.
Correlations between miR-196b expression with either FIGO
stage or nodal status were analyzed using one-way ANOVA.
Results
miR-196b was Significantly Down-regulated in Primary
Cervical Cancer Tissues and Cell Lines, and was Strongly
Associated with DFS
Expression of miR-196b was significantly reduced by almost 4-
fold in 79 primary cervical cancer tissues compared to 11 normal
cervix tissues (P,0.001; Fig. 1A). Importantly, patients with lower
than median miR-196b expression level at the time of diagnosis
experienced worse DFS compared to those with higher miR-196b
expression (P=0.02; hazard ratio = 0.39; Fig. 1B). miR-196b
expression was not significantly correlated with tumor size
(P=0.12), FIGO stage (P=0.14), or nodal status (P=0.60).
Global miRNA expression profiling conducted on three cervical
cancer cell lines (ME-180, SiHa and HT-3) also confirmed the
down-regulation of miR-196b in cervical cancer. From the 55
miRNAs that were deregulated at least 2-fold in all three cell lines
compared to 3 normal cervix tissues, miR-196b was amongst the
most significantly down-regulated miRNAs (Fig. 1C), consistent
with a previously published miRNA expression profiling study
[13].
To explore whether miR-196b down-regulation was epigenet-
ically determined, in addition to chromosomal loss [19], ME-180
and SiHa cells were treated with the demethylating agent 5-aza-29-
deoxycytidine (5-aza-DCT). This treatment resulted in only a
minimal increase in miR-196b expression, indicating that
promoter methylation was unlikely to be a major mechanism for
miR-196b under-expression (Fig. S1A). Furthermore, examination
of publically-available microarray datasets of gene expression in
primary cervical cancer tissues did not reveal any significant
alterations in the expression of DICER, drosha, DGCR8,
Exportin-5, or any subunits of RNA Polymerase II, which are
all involved in miRNA biogenesis and processing (data not shown).
miR-196b Over-expression Significantly Reduced Cell
Viability, Clonogenicity, Proliferation and Invasion
To assess the biological significance of miR-196b down-
regulation, cells were transfected with 30 nmol/L NC or pre-
miR-196b. Up-regulation of miR-196b expression was sustained
for up to 72 hours after transfection (Fig. S1B). Transfection with
pre-miR-196b led to significantly decreased cell viability compared
to controls at 48 and 72 hours post-transfection (ME-180:25% at
48 h; 41% at 72 h, SiHa: 29% at 48 h; 54% at 72 h) (Fig. 2A). In
addition, miR-196b over expression resulted in significant
reductions in clonogenicity (ME-180:57% compared to NC, SiHa:
64% compared to NC) (Fig. 2B), proliferation (ME-180:36% at
48 h, 35% at 72 h, SiHa: 22% at 48 h; 21% at 72 h) (Fig. 2C),
and migration (32% compared to NC), plus invasion (32% vs. 63%
for NC) (Fig. 2D). Cells treated with pre-miR-196b demonstrated
a small, but not statistically significant, increase in the percentage
of cells in the sub G1 population, accompanied by a small decrease
in the G0–G1 population (Fig. S1C).
miR-196b Over Expression Suppressed Tumor
Angiogenesis and Tumor Cell Proliferation in vivo
Cells transfected with pre-miR-196b did not show a statistically
significant difference in tumor growth in mice, compared to NC-
treated cells (Fig. S2). At 25 days post-implantation however,
CD31 immunostaining was nonetheless observed to be reduced to
69% in pre-miR-196b-treated tumors compared to control tumors
(Fig. S3, top). Furthermore, this was associated with a modest yet
significant reduction in Ki-67 expression (46% vs. 53% for cells
treated with NC) (Fig. S3, middle), and a minor, but not
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statistically significant increase in TUNEL staining (Fig. S3,
bottom). Hence, our data suggested that pre-miR-196b contrib-
uted to reduced angiogenesis and tumor cell proliferation.
miR-196b Directly Targets HOXB7
The down-regulation of miR-196b in cervical cancer tissues and
cell lines, and the significant phenotypic effects of miR-196b over-
expression both in vitro and in vivo, indicated that miR-196b
appears to be an important mediator of cervical cancer
progression. Thus, a tri-modal strategy [8] was utilized to identify
potential mRNA targets that could account for these phenotypic
changes (Fig. S4). This method identified 15 overlapping
candidate targets (ANKHD1, CALM3, CLK2, CTDSP2, FGFR1,
HDAC, HOXA7, HOXB7, KRT8, PCCB, PUM2, SLC9A6,
SMC3, SMG7, SR140). For target validation, ME-180 cells were
transfected with pre-miR-196b or NC, and transcript levels at 24
hours post-transfection were measured with qRT-PCR for 12
candidate targets (suitable primers could not be designed for the
other 3 transcripts), plus 4 previously-described targets of miR-
196b (c-myc, BCL2, HOXA9, MEIS1). None of the previously-
described targets were significantly altered after miR-196b over-
expression (Fig S5A). Only 5 of the 12 tested candidate targets
were significantly down-regulated after miR-196b over-expression
(Fig. S5B); HOXB7 was selected for further functional evaluation
since it was the candidate target that demonstrated the greatest
level of down-regulation (40% compared to controls). Further-
more, HOXB7 is a member of the Hox gene cluster, a family of
genes which have been reported to be dysregulated in various
malignancies [20], and the miR-196 family is known to target the
mammalian Hox genes [21].
A luciferase binding assay confirmed that miR-196b directly
and specifically interacted with the 39-UTR of HOXB7. In
comparison to control cells transfected with pMIR-REPORT,
cells transfected with pMIR-HOXB7 showed reduced luciferase
activity (ME-180:68%, SiHa: 71%) when co-transfected with pre-
miR-196b (Fig. 3A). This inhibitory effect was completely
abrogated with pMIR-HOXB7-mut, which contained a mutation
in the miR-196b binding site. In addition, transfection with pre-
miR-196b resulted in significantly reduced HOXB7 mRNA
transcript (ME-180:49% at 48 h, 62% at 72 h; SiHa: 55% at
48 h, 69% at 72 h) (Fig. 3B), and protein (74% at 48 h; 80% at
72 h) (Fig. 3C) levels at 48 and 72 hours post-transfection. There
appeared to be a greater fold change in HOXB7 at the mRNA
level compared to protein, which is not surprising since miRNAs
interact directly with mRNA transcripts and not proteins. In
addition, protein translation can be affected by a number of
mechanisms that occur upstream, such as nuclear export of RNA
transcripts and recruitment of ribosomal subunits.
VEGF is a Relevant Downstream Target of HOXB7
Since HOXB7 is a transcription factor, it was necessary to
determine which gene(s) regulated by HOXB7 could be relevant
in this context for cervical cancer. Hence, cells were transfected
with 30 nmol/L of siHOXB7 or siNEG, and mRNA levels of
known HOXB7 targets such as Ku70, Ku80, DNA-PK, FGF2,
MMP2, WNT5a, PDGFA, thrombospoindin 2 (THBS2) and
VEGF [22,23,24,25] were measured at 48 hours post-transfection.
VEGF demonstrated the greatest level of down-regulation (43%)
following HOXB7 knockdown (Fig. S6A). Concordantly, signifi-
cant reduction in VEGF mRNA (ME-180:63% at 48 h, 33% at
72 h; SiHa: 69% at 48 h, 41% at 72 h) (Fig. 4A) and secreted
protein (ME-180:82% at 48 h, 77% at 72 h; SiHa: 84% at 48 h,
75% at 72 h) (Fig. 4B) levels were observed at both 48 and 72
hours post-transfection with siHOXB7, confirming that VEGF
was indeed a relevant downstream HOXB7 target in this disease.
Furthermore, other pro-angiogenic known targets of HOXB7
(FGF2, MMP2, WNT5a, PDGFA, THBS2) were not significantly
altered following HOXB7 knockdown (Fig. S6A) or miR-196b
overexpression (Fig. S6E), suggesting that HOXB7 mediated
angiogenesis via VEGF in this context.
Knockdown of HOXB7 or VEGF Recapitulated the
Biological Effects Observed Following miR-196b Over
Expression
To further corroborate this newly-described pathway of miR-
196b targeting HOXB7 which in turn regulated VEGF, ME-180
and SiHa cells were treated with siHOXB7 or siVEGF to
determine whether these interventions could recapitulate the
effects of miR-196b over-expression. Knockdown of HOXB7 and
VEGF transcript and protein levels were sustained for up to 72
hours after siRNA transfection (Fig. S6B, S6C, and S6D). We
observed that cell viability was reduced significantly after
transfection with either siHOXB7 (ME-180:77% at 48 h, 66%
at 72 h; SiHa: 80% at 48 h, 70% at 72 h) (Fig. 5A, left) or siVEGF
(ME-180:78% at 48 h, 60% at 72 h; SiHa: 77% at 48 h, 68% at
72 h) (Fig. 5A, right), similar to the effects observed after
transfection with pre-miR-196b (ME-180:25% at 48 h, 41% at
72 h; SiHa: 29% at 48 h, 54% at 72 h) (Fig. 2A). Clonogenicity
decreased significantly following either siHOXB7 (ME-180:69%;
SiHa: 71%) (Fig. 5B, left) or siVEGF (ME-180:78%; SiHa: 75%)
(Fig. 5B, right) transfection, as previously observed for pre-miR-
196b transfection (ME-180:57% compared to NC; SiHa: 64%
compared to NC) (Fig. 2B). Cell migration (Fig. 5C, top) was also
reduced significantly following transfection with either siHOXB7
(60%) or siVEGF (62%), similar to the results observed following
pre-miR-196b transfection (32% vs. NC) (Fig. 2D, top). Finally,
cell invasion also significantly decreased after transfection with
either siHOXB7 (52% vs. 74% for control cells) or siVEGF (42%
vs. 74% for control cells) (Fig. 5C, bottom), all recapitulating the
effects observed after transfection with pre-miR-196b (32% vs.
63% for control cells) (Fig. 2D, bottom).
Discussion
In this study, we identified that miR-196b was significantly
down-regulated in both cervical cancer cell lines and primary
tissues, which promoted tumour cell proliferation, migration,
invasion, and angiogenesis, mediated through VEGF regulation by
HOXB7. MicroRNA-196b was one of the six deregulated
miRNAs first reported by Lui et al for human cervical cancer
[13]. Its biological role was first described for endometriosis [26];
since then, miR-196b has been reported to be deregulated in
various human malignancies aside from cervical cancer, including
over-expression in acute lymphoblastic leukemia (ALL) [27] and
colon cancer [28]; as well as under-expression in glioblastoma [29]
and B-cell lineage ALL [30]. These discordant observations
highlight the fact that miR-196b can function as either an
oncogene or a tumor suppressor, as described for many miRNAs.
In glioblastoma, miR-196b levels have been positively correlated
with overall survival [29]. In contrast, we report for the first time
that lower levels of miR-196b were associated with worse DFS for
cervical cancer, by promoting cellular proliferation, clonogenicity,
migration and invasion in vitro, as well as tumor cell proliferation
and angiogenesis in vivo.
The mechanisms for miR-196b down-regulation are complex.
Using array comparative genomic hybridization (aCGH) profiling
of cervical cancer samples, the chromosomal location of miR-196b
(7p15.2) was noted to be a region with a high level of homozygous
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loss in squamous cell cervical carcinoma [19]; hence this might be
one explanation for down-regulation of miR-196b in this disease.
miR-196b has also been reported to be epigenetically regulated in
gastric cancer [31], which was not corroborated based on our data
(Figure S2).
Few studies have identified mRNA targets of miR-196b, aside
from c-myc [30], and the Hox gene cluster [21]. The Hox gene
family consists of a set of 39 genes which encode transcription
factors that direct the basic structure and orientation of an
organism during embryonic development [32], regulating many
crucial processes such as differentiation, apoptosis, motility,
angiogenesis and receptor signaling [20]. Aberrant Hox gene
expression has been reported to mediate oncogenesis in many
human cancers, including hepatocellular [33], ovarian [34], as
well as acute myeloid leukemia (AML) [35]. There are at least
three mechanisms that have been described which can lead to Hox
gene deregulation: a) over-expression of Hox genes in a specific
tissue type; b) epigenetic deregulation, whereby Hox genes are
silenced in a tissue when they should normally be expressed; and c)
temporo-spatial deregulation, whereby Hox gene expression in a
tumor arising in a specific tissue temporo-spatially differs from that
in normal tissue [36]. In this current study, we provide evidence
for an alternate mechanism for HOXB7 deregulation, via miR-
196b, in cervical cancer.
Our current study also demonstrated that VEGF was a
downstream transcriptional target of HOXB7 in cervical cancer,
which has also been reported for breast cancer [23], as well as
multiple myeloma [25]. VEGF is a known key mediator of
angiogenesis [37]; a major hallmark of human cancers [38]. In
contrast, other pro-angiogeneic factors that are known targets of
HOXB7 (FGF2, MMP2, WNT5a and PDGF) were not signifi-
cantly altered following HOXB7 knockdown or miR-196b
overexpression [23,25]. Although VEGF was initially regarded
to be an endothelial-specific ligand, reports have shown that
VEGF can promote cancer cell proliferation [39,40], migration
and invasion [41,42]. Interestingly, serum VEGF levels have been
shown to be a prognostic marker for DFS in cervical cancer
patients, whereby high pre-treatment VEGF levels were associated
with worse survival [43,44]. In addition, alterations in the serum
concentration of VEGF have been used to measure treatment
response in cervical cancer patients [45]. Serum expression of
VEGF might indeed be a superior read-out of angiogenic activity
in cervix tumors, compared to tissue expression of VEGF.
Unfortunately, sera samples were not available from the patients
in this current study.
A humanized anti-VEGF monoclonal antibody (A.4.6.1) that
recognizes all biologically active isoforms of VEGF and prevents
their binding to VEGF receptors (VEGFR-1 and VEGFR-2),
Bevacizumab, has been shown to be effective in treating several
human malignancies by blocking angiogenesis [46]. Thus far,
Bevacizumab has been approved by the FDA for treating
metastatic colorectal cancer, non-small cell lung cancer, glioblas-
toma, and metastatic kidney cancer. A multi-centre randomized
Phase III clinical trial (GOG240) has recently been completed, in
which Bevacizumab in combination with standard treatment was
evaluated in cervical cancer patients with advanced (stage IVB),
persistent, or recurrent cervical cancer. A National Cancer
Institute (NCI) press release in February 2013 announced that
the Phase III trial demonstrated that the addition of Bevacizumab
significantly improved median survival by 3.7 months.
In conclusion, we report for the first time that miR-196b is a
novel tumor suppressor in cervical cancer, by regulating the
transcription factor HOXB7, which in turn, induced VEGF
expression. The resulting phenotype of miR-196b down-regulation
included increased cell growth, clonogenicity, migration and
invasion, as well as increased tumor cell proliferation and
vascularity in vivo. Furthermore, patients with lower miR-196b
expression experienced a worse 5-year DFS. Hence, this novel axis
of miR-196b,HOXB7,VEGF might well provide the biological
rationale for the potential efficacy of an anti-angiogenic thera-
peutic strategy for cervical cancer.
Supporting Information
Figure S1 In vitro effects of 5-aza-29-deoxycytidine
treatment and miR-196b over-expression. A) qRT-PCR
analysis of miR-196b levels in ME-180 and SiHa cells after
treatment with DMSO or 2 mM 5-aza-29-deoxycytidine (5-aza-
DCT). Expression levels were normalized to RNU44 expression,
relative to cells treated with DMSO. B) qRT-PCR analysis of
miR-196b levels in ME-180 and SiHa cells after treatment with
NC or pre-miR-196b (30 nmol/L). Expression levels were
normalized to RNU44 expression, relative to cells treated with
NC. C) Cell cycle analysis performed on ME-180 (top) and SiHa
cells (bottom) using flow cytometry after treatment with pre-miR-
196b or NC (30 nmol/L). The data represented the mean 6 SEM
from 3 independent experiments. NC, pre-miR Negative Control;
**P,0.01; P=ns (not significant).
(TIF)
Figure S2 Effect of miR-196b on in vivo tumor growth.
Tumor-plus-leg diameter measurements of ME-180 tumors in
SCID mice after intramuscular injection of cells transfected with
pre-miR-196b or Negative Control pre-miR (60 nmol/L). The
plotted data represent the mean 6 SEM from 9 mice in each
group.
(TIF)
Figure S3 Effect of miR-196b on in vivo angiogenesis
and apoptosis. Tumours removed at 25 days post-implantation
were immunostained for CD31, Ki-67, and TUNEL expression;
representative photomicrographs are shown for NC vs. miR-196b
for CD31 (top), Ki-67 (middle), and TUNEL (bottom) immuno-
expression. The corresponding histograms represented the mean
6 SEM scoring obtained from 6 representative regions, from 2
independent tumors. NC, pre-miR Negative Control; *P,0.05;
P=ns (not significant).
(TIF)
Figure S4 Tri-modal strategy for target identification. A
tri-modal strategy to elucidate targets of miR-196b in cervical
cancer used a combination of: i) All predicted targets of miR-196b
from five in silico miRNA target prediction databases (in silico); ii)
mRNA transcripts up-regulated at least 2-fold in primary cervical
cancer samples compared to normal cervix tissues [Cervical
cancer (Up)]; and iii) mRNA transcripts down-regulated at least
0.5-fold at both 24 and 72 hours after transfection with 30 nmol/L
of pre-miR-196b (Exp. Det.).
(TIF)
Figure S5 Transcript levels of putative miR-196b tar-
gets. qRT-PCR analysis of: A) previously described; and B)
candidate targets of miR-196b. ME-180 cells were transfected with
NC or pre-miR-196b (30 nmol/L) and transcript levels of
candidate targets were measured at 24 hours post-transfection.
Expression levels were normalized to GAPDH expression, relative
to cells transfected with pre-miR Negative Control. The data
represent the mean 6 SEM from 3 independent experiments.
*P,0.05.
(TIF)
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Figure S6 In vitro effects of treatment with siHOXB7,
siVEGF, or pre-miR-196b. A) qRT-PCR analysis of candidate
targets of HOXB7. Cells were transfected with siNEG or siHOXB7
(30 nmol/L) and transcript levels of candidate targets were
measured at 24 hours post-transfection. B) qRT-PCR analysis of
HOXB7 (left) and VEGF (right) transcript levels after treatment
with siHOXB7, siVEGF, or siNEG (30 nmol/L). C) Western blot
analysis of HOXB7 protein levels after treatment with siNEG or
siHOXB7 (30 nmol/L). D) VEGF protein levels as measured by
ELISA, after treatment with siNEG or siVEGF (30 nmol/L). E)
qRT-PCR analysis of candidate targets of HOXB7. Cells were
transfected with NC or pre-miR-196b (30 nmol/L) and transcript
levels of candidate targets were measured at 24 hours post-
transfection. The data represent the mean 6 SEM from 3
independent experiments. NC, pre-miR Negative Control; siNEG,
All Stars Negative Control; *P,0.05; **P,0.01.
(TIF)
Table S1 Primer sequences used for qRT-PCR.
(DOCX)
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